相关实验视频

Updated: May 15, 2025

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo
11:17

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

Published on: August 11, 2018

11.9K

在GLP-1激动剂治疗中对皮肤不良反应进行了回顾性比较分析

Sophia Daniel, Stephanie Waggett, Elliott Lyles

    Journal of drugs in dermatology : JDD
    |April 8, 2025
    PubMed
    概括

    葡萄糖类-1 (GLP-1) 激动剂通常会引起皮肤反应,如湿疹和. 与减肥相比,当GLP-1激动剂用于2型糖尿病时,脱发和过更频繁.

    更多相关视频

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices06:34

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

    Published on: November 29, 2024

    161
    Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment12:34

    Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

    Published on: January 12, 2024

    720

    相关概念视频

    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
    272
    Pharmacovigilance01:19

    Pharmacovigilance

    Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
    This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
    In some cases, there...
    753
    Oral Hypoglycemic Agents: Glinides01:06

    Oral Hypoglycemic Agents: Glinides

    Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
    112
    Insulin: Dosing Regimen and Adverse Effects01:16

    Insulin: Dosing Regimen and Adverse Effects

    Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
    The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
    129
    Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

    Oral Hypoglycemic Agents: Biguanides and Glitazones

    Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
    142
    Dipeptidyl Peptidase 4 Inhibitors01:23

    Dipeptidyl Peptidase 4 Inhibitors

    Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
    139